Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.77 |
| ▸ | HSD11B1 | P28845 | 13/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612073 | 0.89 | NR1H2 (0.74) | NR1H2HSD11B1NR1I2 | |
| SCHEMBL4612817 | 0.87 | NR1H2 (1.00) | NR1H2HSD11B1 | |
| SCHEMBL4611867 | 0.84 | NR1H2 (0.56) | NR1H2HSD11B1NR1I2 | |
| SCHEMBL14294989 | 0.83 | HSD11B1 (0.76) | NR1H2HSD11B1 | |
| SCHEMBL4611255 | 0.82 | NR1H2 (0.73) | NR1H2NR1I2 | |
| SCHEMBL4610980 | 0.82 | NR1H2 (0.65) | NR1H2HSD11B1NR1I2 | |
| SCHEMBL4612466 | 0.81 | NR1H2 (0.90) | NR1H2HSD11B1 | |
| SCHEMBL5567998 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5564601 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5567960 | 0.81 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476423-B1 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | AMGEN INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1476423-B1 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | AMGEN INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | NR1H2 112/4885HSD11B1 199/4885NR1I2 779/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | NR1H2 112/4885HSD11B1 199/4885NR1I2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.